Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion ...

FDA Drug Recall #D-0315-2021 — Class I — February 18, 2021

Recall Summary

Recall Number D-0315-2021
Classification Class I — Serious risk
Date Initiated February 18, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Zydus Pharmaceuticals (USA) Inc
Location Pennington, NJ
Product Type Drugs
Quantity 816 packs

Product Description

Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 20mL Single-Dose Vials per pack NDC 68382-049-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India. Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.

Reason for Recall

Crystallization: customer complaints for crystallization in finished product.

Distribution Pattern

USA Nationwide

Lot / Code Information

Lot#: L000155, Exp 12/2021; L000156, Exp 1/2022

Other Recalls from Zydus Pharmaceuticals (USA) Inc

Recall # Classification Product Date
D-0400-2026 Class II Icosapent Ethyl Capsules, 1 gram, 120 Capsules ... Mar 9, 2026
D-0295-2026 Class II Icosapent Ethyl capsules, 1 gram, 120-count bot... Dec 30, 2025
D-0247-2026 Class III traZODONE Hydrochloride Tablets, USP, 100mg, 1,... Dec 19, 2025
D-0159-2026 Class II Bromocriptine Mesylate Capsules, USP, 5 mg, 30 ... Oct 23, 2025
D-0152-2026 Class II clomiPRAMINE Hydrochloride, Capsules, USP, 25 m... Oct 22, 2025

Frequently Asked Questions

Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.